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Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus of the genus
Alphavirus, family Togaviridae, that is responsible for sporadic outbreaks in human and equid
populations in Central and South America. In order to ascertain the role that complement plays in
resolving VEEV-induced disease, complement-deficient C3”/” mice were infected with a VEEV
mutant (V3533) that caused mild, transient disease in immunocompetent mice. In the absence of
a functional complement system, peripheral inoculation with V3533 induced much more severe
encephalitis. This enhanced pathology was associated with a delay in clearance of infectious virus
from the serum and more rapid invasion of the central nervous system in C3”/” mice. If V3533 was
inoculated directly into the brain, however, disease outcome in C3”/” and wild-type mice was
identical. These findings indicate that complement-dependent enhancement of peripheral virus
clearance is critical for protecting against the development of severe VEEV-induced encephalitis.
INTRODUCTION
Venezuelan equine encephalitis virus (VEEV) is a mosquito-
borne alphavirus of the family Togaviridae that is endemic
to Central and South America (Griffin, 2001). Although
normally maintained in an enzootic transmission cycle
between various rodent host species and the Culex mosquito
vector, VEEV periodically emerges from its natural cycle to
cause local epidemics in human and equid populations
(Carrara et al., 2005; Weaver & Barrett, 2004). The most
recent major outbreak occurred in 1995 in Colombia and
Venezuela, where 75 000–100 000 human cases were
reported (Weaver et al., 1996). VEEV infection in humans
causes a spectrum of disease ranging from asymptomatic
to flu-like illness to overt encephalomyelitis in approxi-
mately 4 % of cases, with an overall case mortality rate
of approximately 0.5–1 % (Weaver et al., 2004). In equid
populations, the development of overt encephalomyelitis is
more common, and the overall mortality rate often exceeds
50 % (Wang et al., 2001). Although specific viral sequence
determinants associated with epidemic emergence have been
identified, outbreaks remain unpredictable (Anishchenko
et al., 2006). As a result, VEEV remains a significant public
health threat in the region.
Much of our current understanding of VEEV pathogenesis
and immunity comes from studies carried out in a well-
characterized mouse model of infection. VEEV infection of
the mouse closely replicates the lymphotropic aspects of
infection in humans and the lymphotropic and encepha-
litic aspects of equid infection (Gleiser et al., 1962).
Subcutaneous (s.c.) injection of VEEV into the mouse
footpad is followed by efficient replication in the skin-
draining popliteal lymph node and rapid dissemination to
the spleen and other secondary lymphoid organs (Aronson
et al., 2000; MacDonald & Johnston, 2000). Replication at
these sites leads to the development of a serum viraemia
within the first 12 h of infection. Virus invasion of the
central nervous system (CNS) first occurs through the
olfactory neuroepithelium, a mucosal surface that is den-
sely innervated with olfactory sensory neurons (Charles
et al., 1995). It is thought that these cells are infected
following diffusion of virus through the permeable
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fenestrations of adjacent capillaries. The virus then dis-
seminates into the olfactory bulb of the brain by centripetal
spread, usually within 36 h of infection (Charles et al.,
1995). Once the virus has crossed into the CNS, it
replicates predominantly within neurons, triggering the
death of the animal from a paralysing encephalomyelitis
within 6–8 days post-infection (p.i.) (Charles et al.,
2001; Grieder et al., 1995). The mortality rate in both
inbred and outbred strains of mice is 100 %, and results
from a combination of virus-mediated cytolysis of infected
neurons and the detrimental effects of the host immune
response within the CNS (Charles et al., 2001; Wang et al.,
2001).
Engagement of both the innate and adaptive arms of the
immune response is required for successful control of
VEEV infection. The type I interferon system plays a
critical role in limiting early virus replication and
dissemination (White et al., 2001). Antiviral antibodies
can limit virus dissemination in the periphery, as well as
aid in clearance of virus from infected neurons (Levine et al.,
1991; Mathews & Roehrig, 1982). The role of ab T cells
during VEEV infection is unclear, as they can contribute to
control of VEEV infection within the CNS, as well as to
VEEV-induced immune pathology (Brooke et al., 2010;
Charles et al., 2001; Paessler et al., 2007). Further efforts to
identify the components of a successful immune response to
VEEV infection have been limited by the extreme lethality of
the virus in mice.
The host complement system is a complex network of over
30 soluble and cell-associated factors that contribute to both
innate and adaptive control of microbial infection (Carroll,
2004). Activated complement components act to limit
infection through a number of mechanisms including
opsonization, direct killing of pathogens, and recruitment
and regulation of inflammatory cells (Carroll, 2004; Kemper
& Atkinson, 2007; Roozendaal & Carroll, 2006). Comple-
ment plays a critical protective role during infection with a
number of viruses, including influenza A virus, West Nile
virus, ectromelia virus and herpes simplex virus (Kopf et al.,
2002; Mehlhop & Diamond, 2006; Moulton et al., 2008;
Verschoor et al., 2003). In contrast, complement activation
enhances virus-induced pathology following infection with
the alphaviruses Ross River virus and Sindbis virus (Hirsch
et al., 1978; Morrison et al., 2007).
In this study, we used an established model of acute,
non-lethal VEEV infection to ascertain the role of the
complement system in VEEV pathogenesis and immunity.
S.c. infection of wild-type C57BL/6J mice with the V3533
strain of VEEV results in the development of a mild, self-
limiting illness with minimal signs of CNS complications
(Brooke et al., 2010). In contrast, infection of complement-
deficient C32/2 mice with V3533 resulted in the devel-
opment of severe encephalitis, suggesting that the
complement system plays an important role in limiting
VEEV-induced pathology. No differences in disease outcome
were observed following intracranial infection, however,
indicating that complement was acting at a step prior to
neuroinvasion. Further studies revealed delayed serum
clearance and earlier neuroinvasion in C32/2 mice that
could not be explained by defects in anti-VEEV antibody
induction or the loss of C5-dependent complement function.
Together, these findings demonstrate that complement-
dependent enhancement of virus clearance from the
periphery plays a critical role in limiting the severity of
VEEV-induced encephalitis by restricting virus dissemina-
tion to the CNS.
RESULTS
C3”/” mice develop more severe
encephalomyelitis following V3533 infection
Previous work has demonstrated that s.c. infection of
C57BL/6J mice with V3533 results in the development of
mild disease associated with virus neuroinvasion and
replication within the CNS, followed by clearance and
recovery (Brooke et al., 2010). Using V3533 infection of
C57BL/6J mice as a model of successful control of VEEV
infection, we used congenic complement-deficient C32/2
mice to determine what role, if any, the host complement
system plays during VEEV infection. C32/2 and C57BL/6J
mice were infected s.c. with 106 p.f.u. V3533 in the footpad
(Fig. 1). Weight loss in C57BL/6J mice was minimal, and
clinical signs of disease were mild, consisting of hunched
posture, ruffled fur and mild motor dysfunction in a subset
of infected animals. In contrast, C32/2 mice uniformly lost
significantly more weight and developed more severe signs
of encephalitis, with all infected animals developing
pronounced ataxia and in some cases hind limb paresis or
paralysis. In both C57BL/6J and C32/2 mice, these signs of
disease were transient, and all infected mice went on to
recover. The significantly enhanced severity of encephalitic
disease observed in C32/2 mice compared with that in with
C57BL/6J mice clearly demonstrated that the host
complement system was playing a protective role during
V3533 infection.
Enhanced disease severity in C3”/” mice is
associated with more extensive inflammation and
pathology within the brain
In several different models of alphavirus infection of the
CNS, disease is associated with extensive inflammatory-cell
infiltration within the brain parenchyma (Charles et al.,
2001; Fazakerley & Buchmeier, 1993; Grieder et al., 1995;
Irani & Griffin, 1996). To determine whether the differences
in weight loss and clinical course of wild-type and C32/2
mice following V3533 infection correlated with differences
in inflammation and neuropathology within the brain,
haematoxylin and eosin (H&E)-stained brain sections from
V3533-infected mice were blinded and scored by an outside
investigator (Fig. 2). In both wild-type and C32/2 mice,
signs of inflammation first became apparent between 4 and 8
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days p.i. By day 8, focal and diffuse inflammatory-cell
infiltration was observable in the olfactory bulb, cerebellum,
brainstem and occasionally the cortex of both wild-type and
C32/2 mice (Fig. 2c, d). At this time point, the cellular
density of inflammatory cells within the glomerular layer of
the olfactory bulb was significantly higher in C32/2 mice
compared with that in the wild-type mice (P50.01, two-
tailed t-test) (Fig. 2a). The glomerular layer is the site of
synapse between sensory neurons of the olfactory neuro-
epithelium and olfactory tract neurons within the CNS, and
is thought to be the site at which VEEV first enters the CNS
during infection. Throughout the rest of the brain, the mean
number of inflammatory foci was higher in C32/2 mice
relative to wild-type mice, but this difference did not achieve
significance (Fig. 2b). By day 12 p.i., when V3533-infected
mice had begun to recover, inflammatory infiltration was
still observed throughout the brains of both mouse strains,
although the overall cellularity and numbers of foci tended
to be higher in the C32/2 mice. Thus, the differences in
outward disease signs between wild-type and C32/2 mice
following V3533 infection correlated with the severity of
inflammation within the brain, primarily the olfactory bulb.
Viral burdens within the CNS of C3”/” mice are
higher and less variable than those of wild-type
mice
V3533 infection of C57BL/6J mice results in virus replication
within the brain and spinal cord, followed by clearance of
infectious virus by 8 days p.i. (Brooke et al., 2010). Given
the differences in disease outcome between C57BL/6J and
C32/2 mice following V3533 infection, we next asked
whether the more severe disease in C32/2 mice was asso-
ciated with a larger viral burden within the CNS or with a
defect in virus clearance. To answer this question, C57BL/6J
and C32/2 mice were infected s.c. in the footpad with
106 p.f.u. V3533. The animals were sacrificed at 0.5, 1, 2, 4, 6
and 8 days p.i. and viral burdens in serum, spleen, draining
popliteal lymph node, brain and spinal cord were assessed by
plaque assay (Fig. 3).
In C57BL/6J mice, virus was first detected in the brain on
day 2, with peak titres being reached between days 4 and 6.
On day 4, titres were highly variable, ranging from below the
limit of detection up to 106 p.f.u. g21, but by day 6, the titres
were much more consistent, with a geometric mean of
8.656103 p.f.u. g21. In the spinal cord, virus was detectable
only on days 4 and 6, with no virus being detectable in a
subset of mice at each time point (two of nine mice at day 4,
three of seven mice at day 6). In both brain and spinal cord,
infectious virus was undetectable by day 8. In contrast,
C32/2 mice had detectable virus in both the brain and spinal
cord within 24 h of infection. Virus titres in both tissues
peaked at day 4, with mean titres in both brain and spinal
cord higher than those observed in C57BL/6J mice (brain:
P50.0022, spinal cord: P50.0552; two-tailed t-test). Virus
titres in the brains of C32/2 mice at day 4 were also much
less variable than those observed in C57BL/6J mice, as all
mice tested had titres of at least 105 p.f.u. g21. Clearance
kinetics were similar between C57BL/6J and C32/2 mice,
although on day 8 some C32/2 animals still had detectable
virus titres in the brain (four of seven mice) and spinal cord
(one of seven mice). Thus, the more severe disease observed
in C32/2 mice was associated with more rapid neuroinva-
sion and with higher and more consistent viral burdens
within the CNS.
C3”/” mice exhibit a delay in virus clearance from
the serum relative to wild-type mice
To assess the effect of host complement on early replication
of V3533 in the periphery, we compared viral burdens
within the serum of C57BL/6J and C32/2 mice, as well as the
draining popliteal lymph node and spleen, two anatomical
sites of replication thought to contribute to serum viraemia
(Fig. 3). In the serum, peak titres in both C57BL/6J and
C32/2 mice occurred at 12 h p.i. and were similar, but the
Fig. 1. Complement activation limits disease severity following
V3533 infection. C57BL/6J ($) or C3”/” (#) mice (seven or eight
mice per group) were infected with 106 p.f.u. V3533 in the left rear
footpad. Weight loss (a) and disease score (b) were assessed
following infection. Mice were scored according to the scale
described in Methods. Each data point represents the arithmetic
mean±SEM. Differences between groups were significant for both
weight loss (P50.016) and disease score (P50.0014) by
repeated-measures analysis of variance (ANOVA) testing. The
results are representative of three independent experiments.
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clearance kinetics were quite different. Serum titres in
C57BL/6J were reduced about tenfold between 12 and 24 h
p.i., and by day 2 the virus was undetectable in all but one
animal tested. In contrast, C32/2 mice sustained signifi-
cantly higher serum titres on days 1 and 2 compared with
C57BL/6J mice, and virus was still detectable in three of six
animals on day 4. In the draining lymph node, virus titres in
C32/2 mice were higher than those in C57BL/6J up to day 2,
although by day 4 they were equivalent. In the spleen, the
virus titres were actually lower in C32/2 mice over the first
24 h of infection; however, between days 1 and 6 clearance
was more rapid in the C57BL/6J mice, mirroring the results
observed in the serum.
Host complement plays no significant protective
role following intracranial (i.c.) introduction of
V3533
Given that C32/2 mice were deficient in their ability to
control V3533 in both the periphery and the CNS, it was
possible that the effect of host complement that resulted in
reduced neuropathology could be occurring prior or
subsequent to virus invasion of the CNS. In order to
address where in the infection process host complement
was acting to limit pathology, we introduced 103 p.f.u.
V3533 directly into the CNS of C57BL/6J and C32/2 mice
by i.c. injection. By circumventing peripheral infection,
we were able to assess directly the importance of host
complement within the CNS. Following i.c. infection, both
C57BL/6J and C32/2 mice showed similar outcomes (Fig.
4). Both groups began losing weight within 24 h of
infection, and rapidly began exhibiting clinical signs of
ascending encephalomyelitis. Peak weight loss and disease
scores were observed on days 7–8 in both groups and were
followed by protracted recovery. C57BL/6J and C32/2 mice
were indistinguishable in the kinetics of both disease onset
and recovery, as well as the magnitude of peak weight loss
and disease score, indicating that once V3533 has entered
the CNS, the host complement system no longer plays a
significant role in influencing disease outcome.
Anti-VEEV antibody responses are intact in C3”/”
mice
Complement activation is a requirement for the induction
of antiviral antibody responses following infection with
several different viruses. Whilst the results following i.c.
infection of C57BL/6J and C32/2 mice suggested that the
Fig. 2. V3533-induced brain inflammation in C57BL/6J and C3”/” mice. C57BL/6J or C3”/” mice were injected s.c. with
106 p.f.u. V3533 or diluent alone in the left rear footpad. At different times p.i., three to five mice per group were sacrificed and
5 mm paraffin-embedded sagittal sections were generated and stained with H&E. Sections (two per mouse) were blinded and
evaluated by an outside investigator. (a) Inflammatory-cell infiltration into the olfactory bulb was scored as described in Methods.
Each data point represents the arithmetic mean±SEM. *P,0.05 by two-tailed t-test. (b) Total number of foci of inflammatory-cell
nuclei per brain section. Each data point represents the arithmetic mean±SEM. (c) Representative images of inflammation
and associated pathology at day 8 p.i. in the olfactory bulbs of C57BL/6J and C3”/” mice. (d) Representative images of
inflammation and associated pathology at day 8 p.i. in the brainstem and cerebellum of C3”/” mice. Magnification, 20.
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protective effect of complement was not related to antibody
induction, we wanted to confirm this directly. C57BL/6J and
C32/2 mice were infected s.c. in the footpad with 106 p.f.u.
V3533, and serum was collected on days 2, 4, 8 and 12 p.i. to
assay anti-VEEV binding and neutralization activity.
In both C57BL/6J and C32/2 mice, VEEV-specific IgM was
induced between days 2 and 4 p.i., whilst VEEV-specific IgG
appeared between days 4 and 8 p.i. (Fig. 5a). At all time
points examined, VEEV-specific IgM titres were similar
between C57BL/6J and C32/2 mice, with the exception of
day 12 p.i. where titres were higher in the C32/2 mice. IgG
induction in C32/2 mice appeared to be slightly delayed, as
titres were lower on day 8 compared with those in C57BL/6J
mice. Whilst this difference was statistically significant
(P50.0064, two-tailed t-test), titres in both groups were
quite high. By day 12, IgG levels in both groups were
equivalent. In addition to ELISA, which measured the
amount of anti-VEEV antibody but not its biological
activity, we assessed the anti-VEEV neutralizing activity of
serum collected on day 4 p.i., the time point when viral
burdens within the CNS were most divergent (Fig. 5b).
Similar to the ELISA results, no difference was seen in
neutralizing activity between C57BL/6J and C32/2 mice
(P50.4851, two-tailed t-test). Together, these results
demonstrated that complement is not required for the
development of an anti-VEEV antibody response.
C5 activation has no protective effect during
V3533 infection
Following cleavage of C3, C3b mediates assemblage of the
C5 convertases C4bC2aC3b and C3bBbC3b, which act in
turn to cleave C5 into C5a and C5b. These cleavage
products can exert antiviral activity by at least two distinct
mechanisms. C5a acts by recruiting innate effector cells to
early sites of infection, whilst C5b initiates formation of the
membrane attack complex, a pore-forming complex that
can directly lyse virus particles or virus-infected cells
(Zipfel & Skerka, 2009). Because either of these mechan-
isms could act early to limit virus replication and spread,
we asked whether the protective effects of C3 that we
observed were dependent on C5.
To address this question, we infected C5+/+ and C52/2
mice with 106 p.f.u. V3533 s.c. in the footpad and followed
weight loss and the development of outward signs of
disease over time (Fig. 6a). Both mouse strains responded
similarly, with mild weight loss and short-lived signs of
febrile illness. At no time were any statistical differences
observed between C5+/+ and C52/2 mice. We next asked
whether the loss of C5 resulted in a reduced ability to clear
virus from the serum or in more rapid neuroinvasion. We
infected C5+/+ and C52/2 mice with 106 p.f.u. V3533 s.c.
in the footpad and on days 1 and 4 p.i. compared viral
burdens in the serum and brain (Fig. 6b). In the serum,
Fig. 3. V3533 tissue titres in C57BL/6J and C3”/” mice. C57BL/6J ($) or C3”/” (#) mice were infected s.c. with 106 p.f.u.
V3533 in the left rear footpad. At the indicated times p.i., serum, spleen, draining popliteal lymph node, brain and spinal cord
were collected and homogenized. The viral burden in each tissue was determined by plaque assay. Data points represent
individual titres pooled from three independent experiments, and horizontal bars indicate the geometric mean. *P,0.05;
**P,0.01; ***P,0.001 by two-tailed t-test.
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titres in both mouse strains were indistinguishable on day 1
p.i. and were undetectable by day 4, indicating that C5
played no significant role in mediating clearance of V3533
from the serum. Similarly, C5+/+ and C52/2 mice had
similar virus titres in the brain on days 1 and 4 p.i.,
suggesting that the efficiency of neuroinvasion was not
enhanced in the absence of C5. Together, these results
argue that the C5-dependent elements of the complement
system do not exert a significant protective effect during
VEEV infection.
DISCUSSION
The complement system has been reported to play a
key protective role in the host response to a number of
viral pathogens. For many viruses, including West Nile
virus, influenza A virus and vesicular stomatitis virus,
complement acts by enhancing B- and T-cell responses,
thus facilitating adaptive control of the infection and
clearance (Kopf et al., 2002; Mehlhop et al., 2005; Moulton
et al., 2008; Ochsenbein et al., 1999). In the cases of Sindbis
virus and ectromelia virus, complement appears to act
within the first hours of infection, limiting virus dissem-
ination and thus downstream pathology (Hirsch et al.,
1980; Moulton et al., 2008). In this study, we assessed the
role of the host complement system in a model of recovery
from acute VEEV infection. Overall, our results demon-
strated that the complement system plays an important
role in limiting neuropathology following VEEV infection.
This protective effect resulted from complement acting in
the periphery during the first 24 h of infection to limit the
efficiency of neuroinvasion, and appeared to be independ-
ent of anti-VEEV antibody induction or C5-dependent
effector mechanisms.
The results of this study clearly demonstrated that com-
plement activity in the periphery, but not the CNS,
had a profound effect on the extent of virus-induced
neuropathology. In the absence of complement, clearance of
VEEV from the serum was less efficient and virus appeared
earlier within the CNS. The earlier arrival of VEEV within
the CNS of C32/2 mice, compared with wild-type mice,
would allow the virus to replicate and spread to a greater
degree prior to the generation of VEEV-specific B- and T-
cell responses. A larger viral burden would most likely
trigger a more robust T-cell response within the CNS,
potentially resulting in more severe immunopathology. We
feel that this is a probable explanation for the more severe
encephalomyelitis and neuropathogy observed in C32/2
mice relative to that in C57BL/6J mice.
VEEV invasion of the CNS is thought to occur by diffusion
of virus from the blood through fenestrated capillary
endothelium to nearby unmyelinated peripheral nerve
endings, followed by centripetal spread to the brain
(Charles et al., 1995). One consequence of this route of
neuroinvasion is that the efficiency of invasion is a direct
function of infectious virus concentration within the serum.
This hypothesis is supported by the observation that there
was a minimum virus concentration in the serum of VEEV-
infected mice (approx.¢104 p.f.u. ml21) that was required
for invasion of the brain (K. Bernard, unpublished results).
Thus, any host function that limits either the magnitude or
duration of serum viraemia would also reduce the efficiency
of neuroinvasion. Whilst this connection has not been tested
directly, a number of studies with VEEV, as well as with
Sindbis virus and Western and Eastern equine encephalitis
viruses, have correlated the duration of serum viraemia with
virulence (Byrnes & Griffin, 2000; Jahrling, 1976; Jahrling &
Gorelkin, 1975; Jahrling & Scherer, 1973; Marker & Jahrling,
1979).
In C57BL/6J mice, virus titres in the serum were
significantly reduced from their peak by 24 h p.i., and
were nearly absent by 48 h p.i., prior to the development of
a detectable VEEV-specific antibody response. Thus, it is
possible that natural antibodies play a significant role in
clearing VEEV from circulation. Natural antibodies are
produced constitutively, independently of internal or
external stimuli, and have a fairly wide range of binding
Fig. 4. Disease outcome following i.c. inoculation of V3533.
C57BL/6J (&, $) or C3”/” (h, #) mice (eight mice per group)
were mock-infected (squares) or infected i.c. with 103 p.f.u.
V3533 (circles). Weight loss (a) and disease score (b) were
assessed following infection. Mice were scored according to the
scale described in Methods. Each data point represents the
arithmetic mean±SEM. Differences between C57BL/6J and C3”/”
mice were not statistically significant based on repeated-measures
ANOVA testing.
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avidities, depending on the antigen (Ochsenbein &
Zinkernagel, 2000). One possible explanation for the delay
in serum clearance observed in the C32/2 mice is that
complement activation is required for the maximal antiviral
activity of natural antibodies.
In addition to enhancing natural antibody-mediated neut-
ralization of circulating virus particles, complement activa-
tion might be facilitating serum clearance of VEEV by
antibody-independent mechanisms. Seven distinct comple-
ment receptors (CR1, CR2, CR3, CR4, SIGN-R1, CRIg and
C1qR) have been identified as binding and facilitating
clearance of complement-bound pathogens from the
circulation (Ghiran et al., 2000; Helmy et al., 2006; Holers
et al., 1992; Kang et al., 2006; Kemper & Atkinson, 2007;
Klickstein et al., 1997). These receptors are expressed by
phagocytic cells, such as marginal zone macrophages in the
spleen and Kupffer cells in the liver, and could potentially act
to eliminate complement-bound VEEV particles from the
serum. This mechanism potentially explains the higher virus
burdens observed in the spleens of wild-type mice over the
first 24 h of infection compared with C32/2 mice.
The finding that anti-VEEV IgM and IgG responses were
intact in the absence of complement was surprising given
the complement dependence of antibody responses to
other virus infections. Complement activation can enhance
virus-specific antibody induction through numerous
mechanisms. Recognition of complement-coated antigen
by CR1 and/or CR2 expressed on B cells can lower the
signalling threshold required for activation, whilst CR1 and
CR2 expressed by follicular dendritic cells can act to retain
complement-coated antigen within B-cell follicles, enhanc-
ing presentation to B cells (Barrington et al., 2002; Carter
& Fearon, 1992). CR1 and CR2 have been demonstrated to
be essential for the humoral response to both West Nile
virus and herpes simplex virus (Mehlhop et al., 2005;
Verschoor et al., 2003). It is possible that the replication of
VEEV to such high titres (106–107 p.f.u. per draining
lymph node) in secondary lymphoid organs may provide
sufficiently concentrated viral antigen and inflammatory
stimulus to render CR1/CR2 function unnecessary. Type I
interferon, which is produced in large amounts during
VEEV infection, can also act directly on B cells to promote
antibody production and thus may compensate for the lack
of CR1/CR2 signalling in C32/2 mice (Coro et al., 2006;
Fink et al., 2006; White et al., 2001).
Complement activation can play a major role in the
recruitment and activation of natural killer cells, neutro-
phils, monocyte/macrophages, dendritic cells and other
inflammatory-cell populations (Gutzmer et al., 2006; Li
et al., 2006; McWilliam et al., 1996; Mócsai et al., 2002;
Norgauer et al., 1993; Ross, 2000; Walport, 2001). Thus, it
is possible that the early inflammatory-cell response to
VEEV is at least partially complement dependent, acting
through regulation of the recruitment, activation status
and/or antiviral effectiveness of these inflammatory-cell
populations following recruitment to sites of infection.
Due to the absence of an available C5 knockout in the
C57BL/6 background, we had to assess the role of C5
expression in the B10.D2-H2dH2-T18c/SnJ background.
This difference in genetic background probably explains
the milder disease that we observed in V3533-infected
Fig. 5. The anti-VEEV antibody response is intact in C3”/” mice.
C57BL/6J ($) or C3”/” (#) mice were infected s.c. with 106 p.f.u.
V3533 in the left rear footpad. (a) At the indicated times p.i., mice
were bled and the amount of VEEV-specific IgM and IgG was
determined by anti-VEEV ELISA. Data are presented as the log10
reciprocal dilution at which 50 % of the maximal absorbance value
was reached (EC50). Individual data points represent single animals
and are pooled from two independent experiments. (b) Anti-VEEV
neutralizing activity of serum collected from C57BL/6J and C3”/”
mice on day 4 p.i. Data are presented as the log10 reciprocal
dilution at which 50 % of infectivity was inhibited and bars represent
the arithmetic means±SEM of three to five animals per group.
*P,0.05; **P,0.01 by two-tailed t-test. NS, Not significant.
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wild-type B10.D2-Hc1H2dH2-T18c/nSnJ (C5+/+) mice
compared with C57BL/6 mice. The finding that C5 plays
no protective role during VEEV infection was surprising, as
it meant that two well-described effectors of the complement
system – the anaphylatoxin C5a and the membrane attack
complex – were not involved in controlling the infection.
Instead, these results specifically implicate the C3 cleavage
products C3a and C3b as key mediators of protection during
VEEV infection.
Together, the results described here demonstrate that
interactions between VEEV and the host complement system
during the first hours of peripheral infection can have
profound effects on downstream disease outcome. Speci-
fically, we showed that complement activation limited the
severity of VEEV-induced disease by reducing the efficiency of
viral dissemination into the CNS. This effect appeared to be
independent of anti-VEEV antibody induction or the C5-
dependent functions of the complement system.
METHODS
Viruses. Isolation of the V3533 mutant of VEEV and generation of
the pV3533 molecular clone have been described previously (Aronson
et al., 2000). Virus stocks of V3533 were generated by in vitro trans-
cription from a linearized plasmid, pV3533, which encodes the full-
length V3533 cDNA, using a T7-specific mMessage mMachine in vitro
transcription kit (Ambion). In vitro-generated transcripts were then
electroporated into BHK-21 cells using a Bio-Rad electroporator as
described previously (Aronson et al., 2000; Davis et al., 1989). Culture
supernatants were harvested 18 h after electroporation, clarified and
stored as single-use aliquots at 280 uC.
Mouse studies. C32/2 mice (on the C57BL/6J background) were
obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and
bred in house under specific-pathogen-free conditions. C57BL/6J,
B10.D2-Hc0H2dH2-T18c/oSnJ (C52/2) and B10.D2-Hc1H2dH2-
T18c/nSnJ (C5+/+) mice were purchased from The Jackson
Laboratory as needed. All experimental manipulation of mice was
performed in a Biosafety Level 3 animal facility following a 7-day
acclimatization period. For infections, 6–10-week-old female mice
were anaesthetized via intraperitoneal injection with a mixture of
ketamine (50 mg kg21) and xylazine (15 mg kg21) and then
inoculated either in the left rear footpad with 106 p.f.u. virus in
diluent (PBS with 1 % donor calf serum and Ca2+ and Mg2+) for s.c.
infections, or directly into the brain with 103 p.f.u. virus in diluent for
i.c. infections. Mock-infected mice received diluent alone. Weight loss
and disease score were assessed daily in infected animals. The scale
used for disease scoring was : 0, no signs; 1, hunched posture, ruffled
fur; 2, mild motor dysfunction, altered gait; 3, moderate motor
dysfunction, ataxia; 4, severe motor dysfunction, hind limb paresis/
paralysis; 5, moribund. Mice that lost .35 % of their starting weight
or became moribund were euthanized according to UNC Institutional
Animal Care and Use Committee guidelines.
Virus titres. To assess VEEV titres in vivo, infected mice were
sacrificed, bled and then perfused through the heart with 10 ml PBS.
Spleen, draining popliteal lymph node, brain and spinal cord were
then removed, weighed and frozen at 280 uC in diluent. Tissues were
thawed and homogenized and used to infect BHK-21 cells in a
standard plaque assay (Simpson et al., 1996).
Histological analysis. Mice were sacrificed at the times indicated
by exsanguination and then perfused through the heart with 4 %
paraformaldehyde (pH 7.3). Brains were embedded in paraffin, cut into
5 mm sagittal sections and stained with H&E. Stained sections were
blinded and scored by an outside investigator for the overall extent of
inflammatory-cell infiltration, as well as the total number of inflamma-
tory foci per section. The extent of inflammatory-cell infiltration was
scored on an arbitrary numerical scale of 0–3, with a score of 0
representing no detectable infiltration and a score of 3 representing the
maximal extent of infiltration observed within the experiment.
Antibody analysis. VEEV-specific serum IgG and IgM levels were
assessed by a standard indirect ELISA. Purified, intact VEEV particles
Fig. 6. Complement component C5 plays no
significant role during VEEV infection. C5”/”
(#) and C5+/+ ($) mice were infected s.c.
with 106 p.f.u. V3533 in the left rear footpad.
Weight loss and disease score were deter-
mined following infection (a). Mice were
scored according to the scale described in
Methods. Each data point represents the
arithmetic mean±SEM of data collected from
eight mice per group. Differences in weight
loss (P50.2561) and disease score (P5
0.7521) between C5”/” mice and C5+/+
mice were not statistically significant, based
on repeated-measures ANOVA testing. (b) At
the indicated times p.i., serum and brain were
collected and the viral burden was determined
by plaque assay. Data points represent titres
from individual mice, and horizontal bars
indicate the geometric mean. Differences
between C5”/” mice and C5+/+ mice were
not statistically significant (two-tailed t-test).
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(250 ng per well) were used to coat 96-well NUNC Immulon 4HBX
plates (Thermo Scientific) overnight at 4 uC. After washing, the plates
were incubated with serial dilutions of heat-inactivated mouse serum
containing 10 % blocking buffer (Sigma) overnight at 4 uC. Plates
were washed again, incubated with HRP-conjugated goat anti-mouse
IgM or IgG (Southern Biotech) for 2 h at 4 uC and then developed
using o-phenylenediamine dihydrochloride tablets (Sigma) in equal
volumes of 0.1 M citric acid and 0.1 M sodium citrate. Development
was allowed to proceed for 30 min before the reaction was terminated
with 0.1 M NaF. A450 was measured using a FLUOstar Omega
microplate reader (BMG Labtech). Log10 half-maximum ELISA titres
were calculated using GraphPad Prism software v. 5.0 and represented
the log of the reciprocal dilution at which the half-maximum
absorbance values were achieved.
To assess anti-VEEV neutralizing activity, serum was collected and
either left untreated or heat inactivated at 56 uC for 1 h. The serum
was then serially diluted in diluent and co-incubated with non-
propagating, GFP-expressing VEEV viral replicon particles (GFP–
VRP, as described by Pushko et al., 1997) for 1 h at 37 uC. GFP–VRP/
serum mixtures were then used to infect BHK-21 cells at an m.o.i. of
0.05. At 18 h p.i., infected cells were harvested by trypsinization,
washed, fixed with 2 % paraformaldehyde in PBS and analysed on a
CyAn flow cytometer using Summit 5.2 software (Dako). IC50 titres
were calculated using GraphPad Prism software v.5.0 and represented
the log of the reciprocal dilution at which 50 % inhibition of
infectivity was achieved.
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